HeyJaredThomas Niel
- Indexed articles, last 90 days
- 35
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Aol
- Top 5K sites
- Earliest in this view
- Aug 27, 2026
Latest articles
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - AOL (opens the original)
Read excerpt
Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk. If results stay in line with expectations, Royalty Pharma could surge again on multiple expansion. 10 stocks we like better than Royalty Pharma Plc › Whether it's biotech stocks or regular pharmaceutical stocks, when investors buy a particular name in healthcare, they are making a wager on a single
Most Beginning Investors Ignore Market Cap. That's a Costly Mistake. - AOL (opens the original)
Read excerpt
Beginner investors often use the share price figure to determine a stock's size or relative "cheapness," but this is a major mistake. Instead, use market cap as your starting point to assess a stock's valuation and long-term potential. Utilize more sophisticated valuation metrics, like P/E and EV/EBITDA, when analyzing whether a stock is undervalued or overvalued. These 10 stocks could mint the next wave of millionaires › Many people starting out in investing may look at a stock's share price an
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround - AOL (opens the original)
Read excerpt
Forecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year. At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rating. With management guiding toward a branded pivot that could eventually generate over $10 billion annually, there may be far more runway for Teva's turnaround rally. 10 stocks we like better than Teva Pharmaceutical Industries › Teva Pharmaceuticals(NYSE: TEVA) recently hit a new
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation - AOL (opens the original)
Read excerpt
Bristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still trades at a discounted valuation. Investors remain uncertain about the company's efforts to replace legacy drug sales with the sale of new drug products. This uncertainty could work in your favor, as Bristol Myers Squibb shares could re-rate if the turnaround generates further financial improvement. 10 stocks we like better than Bristol Myers Squibb › Over the past year, Bristol Myers Squibb(NYSE: BMY) shares surg
GE Aerospace Is Spending $12 Billion on an Acquisition. Is It Still the Best Aerospace Stock to Own? - AOL (opens the original)
Read excerpt
On Sep. 8, GE Aerospace announced plans to acquire privately-held Consolidated Precision Products for $11.75 billion. Management has touted how this deal will be instantly accretive to earnings, but that's not the only key positive from this deal. As CPP is a major supplier to GE Aerospace, acquiring it could help the company gain a supply chain edge, which in turn could help it maintain its status as one of, if not the, best aerospace stock. 10 stocks we like better than GE Aerospace › On Sept.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5K sites
For Aol, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.